Abstract:The current noninvasive prognostic evaluation of hepatocellular carcinoma (HCC) using markers such as imaging features and serum biomarkers like alpha-fetoprotein (AFP) is limited due to low sensitivity. Pathologic tumor features can enhance prognosis beyond imaging and AFP, yet pre-surgical percutaneous biopsies are invasive, not routinely pursued, and may not be representative of the entire tumor. There is a critical unmet need to develop noninvasive blood-based HCC biomarkers to guide therapeutic decisions. Epigenetic changes in circulating cell-free DNA (cfDNA) have shown promise in early cancer diagnosis and prognosis. Therefore, we aim to evaluate the potential of cfDNA methylation as a noninvasive predictor for pre-treatment prognostication in HCC patients. Using Illumina HumanMethylation450 array data of 377 HCC tumors and 50 adjacent normal tissues obtained from The Cancer Genome Atlas (TCGA), we systematically identified 158 HCC-related DNA methylation markers associated with overall survival (OS). Functional analyses of these markers indicated their roles in regulating gene expression and revealed biological pathways associated with HCC patient survival. We predicted an OS risk score utilizing the DNA methylation panel, referred to as "methRisk", and validated its predictive power using the Reduced Representation Bisulfite Sequencing data of HCC tumor tissue samples from 29 surgically resected patients. To assess the noninvasive prognostic value of these markers, we collected plasma cfDNA samples from an independent validation cohort of 52 HCC patients, and profiled the methylation patterns of these samples using our newly developed cost-effective cfDNA methylome sequencing assay, cfMethyl-Seq. We utilized random survival forest models combined with 10-fold cross-validation to predict the methRisk using the circulating markers. The cfDNA-based methRisk effectively stratifies patients into clinically relevant risk groups and predicts patient survival with high accuracy (3-year AUC = 0.81, 95% CI: 0.68-0.94). Integrating the cfDNA-based methRisk with existing risk indices like the Barcelona clinic liver cancer (BCLC) staging greatly improves the noninvasive prognostic assessments (3-year AUC = 0.91, 95% CI: 0.80-0.99). In summary, these findings indicate that cfDNA methylation is a promising noninvasive prognostic biomarker for HCC, providing a proof-of-concept for its potential clinical utility. Incorporating cfDNA methylation analysis into the existing noninvasive prognostic framework for HCC patients holds great potential for enhancing the effectiveness of current staging systems and optimizing patient selection for curative therapies like liver transplantation. Citation Format: Ran Hu, Benjamin Tran, Shuo Li, Mary L. Stackpole, Weihua Zeng, Yonggang Zhou, Andrew Melehy, Xianghong Zhou, Wenyuan Li, Vatche Agopian. Cell-free DNA methylation as a noninvasive prognostic biomarker in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB103.

Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy

Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

Significance of m 6A Methyltransferase‑Related lncRNAs in the Prognosis and Immunotherapy of Hepatocellular Carcinoma

Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma

An aberrant DNA methylation signature for predicting hepatocellular carcinoma

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma

Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma

Exploring extrahepatic metastasis of hepatocellular carcinoma based on methylation driver genes and establishing a prognostic model for hepatocellular carcinoma

IGFBP7 Deletion Promotes Hepatocellular Carcinoma

The Cancer Genome Atlas (TCGA) Based M6a Methylation-Related Genes Predict Prognosis in Hepatocellular Carcinoma

The role of CpG island methylator phenotype in the clinical course of hepatocellular carcinoma

Abstract LB103: Cell-free DNA methylation as a noninvasive prognostic biomarker in hepatocellular carcinoma

Identification of Aberrantly Methylated Differentially CpG Sites in Hepatocellular Carcinoma and Their Association With Patient Survival

Prognostic signature and immune efficacy of m1A-, m5C-, m6A-, m7G-, and DNA methylation-related regulators in hepatocellular carcinoma

Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

Hypermethylation of the glutathione peroxidase 4 promoter predicts poor prognosis in patients with hepatitis B virus-associated acute-on-chronic liver failure

A prognostic model based on DNA methylation-related gene expression for predicting overall survival in hepatocellular carcinoma

Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma